Association of Soluble CD14 and Inflammatory Biomarkers with HIV-2 Disease Progression
Overview
Authors
Affiliations
Background: Human immunodeficiency virus type 2 (HIV-2) infection is characterized by a slower progression than HIV type 1. It is not known whether markers of inflammation such as high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), and soluble CD14 (sCD14) may predict disease progression among HIV-2 patients.
Methods: We performed longitudinal retrospective analysis using 384 samples from 71 patients included in the HIV-2 French cohort ANRS CO5 and followed for a median of 8 years. Baseline was the time of the first available measurement. Disease progression was defined by the occurrence of death, Centers for Disease Control and Prevention B/C stage HIV-related event, drop in CD4 <350 cells/µL, and HIV-2 RNA detection. Cox regression models and mixed models were used for statistical analyses.
Results: At baseline, 75% of patients were asymptomatic, 34% were treated; 30% had detectable HIV-2 RNA load, and median CD4 cell count was 415/µL. The 3 biomarkers were positively related to each other. In adjusted analyses, sCD14 was the main factor explaining variation of hsCRP and IL-6 (P < .001). Lower CD4, older age, and advanced clinical stage were associated with higher sCD14. The biomarkers were correlated with HIV-2 RNA in unadjusted analyses only. Patients with baseline levels above either the median values (hsCRP = 1.38 mg/L; IL-6 = 1.97 pg/mL) or the highest quartile (sCD14 = 1.74 µg/mL) had a higher risk of disease progression (all P < .003). After adjustment for CD4 count, only sCD14 remained significantly associated with disease progression (hazard ratio, 3.59; P = .004).
Conclusions: In this cohort of HIV-2-infected patients, sCD14 represents a better predictive biomarker of disease progression than hsCRP or IL-6, independent of CD4.
HIV-2 mediated effects on target and bystander cells induce plasma proteome remodeling.
Johansson E, Nazziwa J, Freyhult E, Hong M, Lindman J, Neptin M iScience. 2024; 27(4):109344.
PMID: 38500818 PMC: 10945182. DOI: 10.1016/j.isci.2024.109344.
Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers.
Picton A, Paximadis M, Koor G, Bharuthram A, Shalekoff S, Lassauniere R Front Immunol. 2022; 12:781263.
PMID: 34987508 PMC: 8720782. DOI: 10.3389/fimmu.2021.781263.
Scharf L, Pedersen C, Johansson E, Lindman J, Olsen L, Buggert M Front Immunol. 2021; 12:744530.
PMID: 34712231 PMC: 8545800. DOI: 10.3389/fimmu.2021.744530.
Conventional Dendritic Cells and Slan Monocytes During HIV-2 Infection.
Iannetta M, Isnard S, Manuzak J, Guillerme J, Notin M, Bailly K Front Immunol. 2020; 11:1658.
PMID: 32903610 PMC: 7438582. DOI: 10.3389/fimmu.2020.01658.
Dou Y, van Montfoort N, van den Bosch A, Janssen H, de Man R, Buschow S J Viral Hepat. 2019; 26(9):1076-1085.
PMID: 31090247 PMC: 6852593. DOI: 10.1111/jvh.13127.